Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.56 +5.13%

+$0.08 today

Market cap
$381.13M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 1.27M

Average 0.65M

ALEC EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Alector, Inc.NASDAQ: ALEC

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$20.85M, compared with -$38.62M a year earlier. Trailing-twelve-month EBITDA was -$116.42M.

Context

  • EBITDA amounted to 632.5% of revenue in FY2025, up 523.0 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $140.67M (+205.7%) for the fiscal year ending Dec 2026, a step up from the -20.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$20.85M+40.2% QoQ
Last fiscal yearDec 2025
-$133.1M-20.9% YoY
LTMMar 2026
-$116.42M-1.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.0%+13.3%-32.7 pp
1 year-20.9%+205.7%+226.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(133.1M) USD
Year-over-year change
-20.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.3% is the 6th highest of 9, against a peer median of +6.7%.
  • EBITDA amounts to 632.1% of revenue for ALEC, versus a peer median of 1366.5%.
ALEC Competitors
EBITDA for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$449.13M USD+489.9%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
PEPGPepGen Inc.LTM Mar 2026-$75.99M USD+22.0%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.28M USD-67.4%——
NKTXNkarta, Inc.LTM Mar 2026-$90.7M USD+10.7%——
IRDOpus Genetics, Inc.LTM Mar 2026-$104.73M USD-226.0%—874.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$108.82M USD+2.8%——
ALECAlector, Inc.LTM Mar 2026-$116.42M USD-1.3%—632.1%
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M USD+23.4%—1859.1%
Peer median (excluding ALEC) —+6.7%—1366.5%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.